Helsinn Healthcare SA

Pambio Noranco, Switzerland

Helsinn Healthcare SA

Pambio Noranco, Switzerland
SEARCH FILTERS
Time filter
Source Type

Patent
Helsinn Healthcare S.A. and Zealand Pharma A S | Date: 2017-07-19

The invention relates to the use of elsiglutide to prevent or reduce the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID).


Patent
Helsinn Healthcare SA | Date: 2017-08-02

The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.


Patent
Helsinn Healthcare SA | Date: 2017-07-12

Methods of treating cancer related conditions using anamorelin are described. The principal embodiment relates to the unique condition of patients defining this condition by treating cachexia in a human cancer patient, comprising administering to said patient a therapeutically effective amount of anamorelin for a therapeutically effective period of time, and observed surprising ability of anamorelin to increase lean body mass in this population.


Patent
Helsinn Healthcare Sa | Date: 2016-12-02

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.


Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved stability and bioavailability, and are preferably in the form of liquid filled capsules.


Patent
Helsinn Healthcare SA | Date: 2017-01-11

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula (I): or pharmaceutically acceptable salts thereof.


Patent
Helsinn Healthcare SA | Date: 2016-08-18

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.


Patent
Helsinn Healthcare SA | Date: 2016-09-15

The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration of chemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.


Patent
Helsinn Healthcare SA | Date: 2016-06-28

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK_(1)) receptor. The compounds have the general formula (I):


Patent
Helsinn Healthcare SA | Date: 2016-09-30

The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.

Loading Helsinn Healthcare SA collaborators
Loading Helsinn Healthcare SA collaborators